On November 2, 2026 Bold Therapeutics, a clinical-stage biopharmaceutical company developing novel metallotherapeutics, reported it will present at BIO-Europe in Cologne, Germany, which is taking place from November 9-11.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Bold Therapeutics addresses high unmet medical needs through innovative mechanisms of action that transform oncology treatment. The company’s lead asset, BOLD-100, is a first-in-class ruthenium-based small molecule in a global randomized Phase 2 clinical trial for patients with second-line metastatic colorectal cancer (mCRC). The study evaluates the efficacy, safety, and tolerability of two BOLD-100 dose levels (500 mg/m² and 625 mg/m²) combined with FOLFOX-based standard of care (SOC) versus FOLFOX-based SOC alone.

The company will share key efficacy and tolerability findings from an interim analysis during its BIO-Europe presentation. "Bold Therapeutics has achieved significant corporate and clinical milestones that advance BOLD-100 toward registrational trials," said Jim Pankovich, EVP of Bold Therapeutics. "Results from this interim analysis build on earlier positive Phase 2 findings in gastrointestinal cancers, including biliary tract, gastric, and colorectal cancers. This progress brings BOLD-100 closer to delivering novel treatment options to underserved patient populations."

Presentation Details:

Date: November 9, 2026 (Day 1)

Time: 1:15PM – 1:30PM

Room: Theater A

(Press release, Bold Therapeutics, NOV 2, 2026, View Source [SID1234674047])